Document Detail

Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.
MedLine Citation:
PMID:  24187047     Owner:  NLM     Status:  Publisher    
PURPOSE: To describe the ocular side effects in patients receiving intravitreal injection therapy (IViT) for retinoblastoma.
METHODS: PubMed (1946-present), Scopus (all years), Science Citation Index (1900-present) and Conference Proceedings Citation Index-Science (1990-present) electronic databases were searched to identify all published reports of therapeutic intravitreal injections for retinoblastoma in humans.
RESULTS: Ten studies with original IViT ocular side effect data were included in this systematic review. In these combined reports, a total of 1287 intravitreal injections were given to 306 eyes of 295 patients, with a mean follow-up of 74.1 months. Two hundred sixty-one (88.5%) patients received comparatively standard melphalan IViT doses (8-30 mcg). Ocular side effects occurred in 38 patients (17 significant, 21 minor). The proportion of patients experiencing potentially significant ocular side effects following standard melphalan IViT regimens was 0.031 (8/261; 95% CI 0.013 to 0.06). The side effects of these eight included iris atrophy in three, two each with chorioretinal atrophy and vitreous haemorrhage and one with retinal detachment. Of the other nine patients with significant complications, five experienced sight-threatening complications following dramatic dose escalations (four with melphalan, one with thiotepa), three experienced complications that are commonly associated with concurrent therapies given to these patients and one had a retinal detachment. Of the 61 patients receiving IViT via safety-enhancing injection techniques, all six significant side effects were either attributed to the therapeutic dose or confounded by concurrent treatments.
CONCLUSIONS: Significant ocular complications following IViT for retinoblastoma are uncommon, and this risk may be reduced further by the use of careful injection technique and standard dosing regimens. Care must be taken in the dosing of intravitreal treatments to avoid potentially irreversible vision loss.
Stephen J Smith; Brian D Smith; Brian G Mohney
Related Documents :
23671547 - Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patient...
24963667 - Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatiti...
23673067 - A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients...
20609757 - Thirty-year follow-up defines survival benefit for second internal mammary artery in pr...
24957307 - The roles and issues of p2y12 percent inhibition assessed by verifynow assay for patien...
10483827 - Adolescent idiopathic thoracic scoliosis: apical correction with specialized pedicle ho...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-11-1
Journal Detail:
Title:  The British journal of ophthalmology     Volume:  -     ISSN:  1468-2079     ISO Abbreviation:  Br J Ophthalmol     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-11-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0421041     Medline TA:  Br J Ophthalmol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Medicine, Bassett Medical Center and Columbia University, Cooperstown, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acoustic and photoacoustic molecular imaging of cancer.
Next Document:  Choroidal thickness in children with hyperopic anisometropic amblyopia.